D. Western Therapeutics Institute (DWTI) (4576 JP) - New Fundraising Secured in June
in Japan, start P2 clinical trials in 2024, P3 trials in late 2025 though 2026, and normal schedule application for approval for regenerative cell...
61 Views
D. Western Therapeutics Institute (4576 JP) - Flurry of Pipeline Activity in 2023
Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma...
414 Views
4Q Follow-Up -D. Western Therapeutics Institute (DWTI) | 4576
Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma...
212 Views
3Q Follow-Up - D. Western Therapeutics Institute (DWTI) (4576 JP)
Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma...
288 Views
2Q Follow-Up - D. Western Therapeutics Institute (DWTI) (4576 JP)
Flurry of pipeline activity continuing in the 3Q. Expedited development plans for DWR-2206, dual formula DW-1002 in the US, and commenced dosing of...
320 Views